Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Ninlaro

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 59,815Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    NICE recommends Takeda’s Ninlaro triplet regimen
    NICE recommends Takeda’s Ninlaro triplet regimen

    20 Jan 2023

    // PHARMATIMES

    https://www.pharmatimes.com/news/nice_recommends_takedas_ninlaro_triplet_regimen_1485592

    PHARMATIMES
    20 Jan 2023
    Share Share
    NICE recommends all-oral treatment for multiple myeloma
    NICE recommends all-oral treatment for multiple myeloma

    19 Jan 2023

    // EUROPEAN PHARMACEUTICAL REVIEW

    https://www.europeanpharmaceuticalreview.com/news/178699/nice-recommends-ixazomib-all-oral-treatment-for-multiple-myeloma/

    EUROPEAN PHARMACEUTICAL REVIEW
    19 Jan 2023
    Share Share
    Active Biotech Begins Dosing in comb. part of phase Ib/IIa study of tasquinimod
    Active Biotech Begins Dosing in comb. part of phase Ib/IIa study of tasquinimod

    07 Feb 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/02/07/2379644/0/en/Active-Biotech-announces-first-patient-dosed-in-the-combination-part-of-the-phase-Ib-IIa-study-of-tasquinimod-in-multiple-myeloma.html

    GLOBENEWSWIRE
    07 Feb 2022
    Share Share
    Takeda Announces Result of Phase 3 Clinical Trial to Evaluate NINLARO (ixazomib)
    Takeda Announces Result of Phase 3 Clinical Trial to Evaluate NINLARO (ixazomib)

    11 Sep 2020

    // BUSINESS WIRE

    https://www.businesswire.com/news/home/20200910006063/nl

    BUSINESS WIRE
    11 Sep 2020
    Share Share
    Takeda's ixazomib comes up short in first-line multiple myeloma study
    Takeda's ixazomib comes up short in first-line multiple myeloma study

    09 Sep 2020

    // SEEKINGALPHA

    https://seekingalpha.com/news/3612814-takedas-ixazomib-comes-up-short-in-first-line-multiple-myeloma-study

    SEEKINGALPHA
    09 Sep 2020
    Share Share
    MHLW Revokes Ninlaro’s Sakigake Status for AL Amyloidosis
    MHLW Revokes Ninlaro’s Sakigake Status for AL Amyloidosis

    26 Jun 2020

    // JIHO

    https://pj.jiho.jp/article/242409

    JIHO
    26 Jun 2020
    Share Share